Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease

Trial Profile

A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apomorphine (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Cynapsus Therapeutics
  • Most Recent Events

    • 19 Jul 2016 Results published in the Movement Disorders (2016).
    • 21 Apr 2016 Results assessing safety of apomorphine presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 21 Apr 2016 Results (subgroup analysis) assessing effects of apomorphine on the rapid reversal of OFF episodes in PD presented at the 68th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top